Correlation Between XSpray Pharma and Hansa Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both XSpray Pharma and Hansa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining XSpray Pharma and Hansa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between XSpray Pharma AB and Hansa Biopharma AB, you can compare the effects of market volatilities on XSpray Pharma and Hansa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in XSpray Pharma with a short position of Hansa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of XSpray Pharma and Hansa Biopharma.

Diversification Opportunities for XSpray Pharma and Hansa Biopharma

0.5
  Correlation Coefficient

Very weak diversification

The 3 months correlation between XSpray and Hansa is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding XSpray Pharma AB and Hansa Biopharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hansa Biopharma AB and XSpray Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on XSpray Pharma AB are associated (or correlated) with Hansa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hansa Biopharma AB has no effect on the direction of XSpray Pharma i.e., XSpray Pharma and Hansa Biopharma go up and down completely randomly.

Pair Corralation between XSpray Pharma and Hansa Biopharma

Assuming the 90 days trading horizon XSpray Pharma AB is expected to generate 0.95 times more return on investment than Hansa Biopharma. However, XSpray Pharma AB is 1.05 times less risky than Hansa Biopharma. It trades about 0.14 of its potential returns per unit of risk. Hansa Biopharma AB is currently generating about 0.08 per unit of risk. If you would invest  3,800  in XSpray Pharma AB on April 23, 2025 and sell it today you would earn a total of  1,410  from holding XSpray Pharma AB or generate 37.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

XSpray Pharma AB  vs.  Hansa Biopharma AB

 Performance 
       Timeline  
XSpray Pharma AB 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in XSpray Pharma AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, XSpray Pharma sustained solid returns over the last few months and may actually be approaching a breakup point.
Hansa Biopharma AB 

Risk-Adjusted Performance

Modest

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Hansa Biopharma AB are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Hansa Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

XSpray Pharma and Hansa Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with XSpray Pharma and Hansa Biopharma

The main advantage of trading using opposite XSpray Pharma and Hansa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if XSpray Pharma position performs unexpectedly, Hansa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hansa Biopharma will offset losses from the drop in Hansa Biopharma's long position.
The idea behind XSpray Pharma AB and Hansa Biopharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm